4//SEC Filing
Orexigen Therapeutics, Inc. 4
Accession 0001209191-17-008198
CIK 0001382911operating
Filed
Feb 6, 7:00 PM ET
Accepted
Feb 7, 6:44 AM ET
Size
11.3 KB
Accession
0001209191-17-008198
Insider Transaction Report
Form 4
Cannell Thomas R
Chief Commercial Officer
Transactions
- Award
Stock Option
2017-02-03+144,000→ 144,000 totalExercise: $4.10Exp: 2027-02-02→ Common Stock (144,000 underlying) - Award
Stock Option
2017-02-03+72,000→ 144,000 totalExercise: $15.00Exp: 2027-02-02→ Common Stock (72,000 underlying)
Footnotes (2)
- [F1]1/48th of the shares of stock subject to the option (rounded down to the next whole number of shares) shall vest on the same day of each month following 2/3/2017, so that all of the shares of the stock subject to the option shall be vested on 2/3/2021, subject to the Reporting Person's continued service relationship (whether as an employee, director or consultant) with the Issuer or any parent or subsidiary on each such date, as set forth in the applicable stock option grant notice and stock option agreement for such Reporting Person.
- [F2]Not Applicable
Issuer
Orexigen Therapeutics, Inc.
CIK 0001382911
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001382911
Filing Metadata
- Form type
- 4
- Filed
- Feb 6, 7:00 PM ET
- Accepted
- Feb 7, 6:44 AM ET
- Size
- 11.3 KB